Here, we found that BRAF inhibitors (BRAFi), typically used to treat melanomas with the BRAFV600E mutation, can prominently promote cell proliferation and erythropoiesis through amplifying MAPK activation via dimerizing with CRAF in wild-type BRAF cells. Here, BRAF is linked to melanoma.